Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
3
×
boston blog main
3
×
boston top stories
deals
3
×
life sciences
national blog main
clinical trials
national top stories
roche
abbvie
alexion pharmaceuticals
allergan
alnylam pharmaceuticals
alzheimer's disease
biopharma
boehringer ingelheim
crispr
cynthia collins
dicerna pharamceuticals
duchenne
editas medicine
europe blog main
europe top stories
fda
gene editing
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
leber congenital amaurosis type 10
licensing
m&a
michelle robertson
muscular dystrophy
parkinson's disease
patisiran
rare diseases
rna interference
san francisco blog main
sarepta therapeutics
What
gene
3
×
medicines
research
roche
abbvie
alliance
approval
betting
billion
biopharma
biotech
caught
causing
deal
dicerna
disease
drug
duchenne
editas
editing
exits
experimental
eye
fda
genetic
hepatitis
historic
intended
medicine
pact
partnership
pay
pharma
pharmaceuticals
producing
protein
pruning
puts
recently
returning
Language
unset
Current search:
biotech
×
deals
×
gene
×
" boston blog main "
×
boston
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug